Neovate Capital Partners Research
Investment Thesis
Neovate Capital Partners is an early-stage life sciences venture fund investing in transformational medical devices and category-defining therapeutics at critical pre-inflection points, typically after technical risk has been mitigated but before the company has reached key commercial or clinical milestones. The firm organizes its thesis around three focus areas: interventional solutions that create new paradigms in care such as neuromodulation and tissue regeneration; robotic and AI-enabled systems that deliver greater precision and efficiency in procedures; and drugs and biologics administered through procedures rather than prescriptions to slow or reverse disease and improve outcomes. The partners position their edge as deep operating and clinical expertise across life sciences segments, which they say lets them identify breakthrough technologies before broader market consensus forms, paired with hands-on support in strategy, commercial scaling, team building, financing, and exit planning.
Sector Focus
Neovate is squarely a medtech and life sciences investor. Core areas include orthopedics and musculoskeletal care, surgical robotics, tissue regeneration and cell therapy, ophthalmology, anti-infectives, and post-operative recovery technologies. The firm does not appear to invest outside life sciences and medtech based on its stated thesis and full portfolio.
Stage Focus
The firm targets seed-stage through Series A investments, generally entering after a company has cleared major technical risk (e.g., proof of concept, early regulatory clearance) but before major commercial or clinical inflection points.
Check Size
Check size and current fund size are not disclosed on the firm's website or in public sources. The firm has cited over $150M in total capital deployed across prior funds and individual positions by its partners, but a specific per-deal check range could not be confirmed.
Lead Tendency
Not clearly disclosed. The firm frequently co-invests alongside Mountain State Capital (a fund co-founded by partner Matt Harbaugh) and, in several portfolio companies, alongside Johnson & Johnson Innovation. Lead tendency is marked unknown pending more direct evidence.
Recent Activity
The most recent confirmed investment is TYBR Health's $30M Series A (announced August 12, 2026), which Neovate participated in to expand access to TYBR's B3 GEL System. Beyond that, the firm's public activity is largely thought-leadership and conference appearances rather than newly announced deals: partner Kevin Rocco spoke at the LSX World Congress USA on the medtech M&A landscape (September 2025), and partners Nick Pachuda and Kevin Rocco discussed diligence practices on the Orthopedics This Week podcast (May 2025), alongside a feature article on the firm's orthopedic investing approach (May 2025).
Portfolio Highlights
Neovate's portfolio spans 16+ companies, concentrated in orthopedics, surgical robotics, and tissue regeneration. Notable exits include Biorez, a New Haven-based soft-tissue repair implant company (BioBrace) acquired by CONMED in August 2022 for up to $250M in combined upfront and earnout consideration, and Orthotaxy, a robotic-assisted knee surgery platform acquired by Johnson & Johnson Medical Devices in 2018. Partners were also involved in earlier exits prior to founding Neovate, including Small Bone Innovations ($350M to Stryker) and Scient'x ($180M to Alphatec), and led teams behind the $21B Synthes-to-J&J transaction. Active portfolio companies include Avisi Technologies (glaucoma device), Caira Surgical (surgical navigation), Discgenics and Discure (degenerative disc disease), Nanochon (cartilage regeneration), Ocugenix (ophthalmic drug for wet AMD), Osteal Therapeutics (anti-infective drug/device combination), PECA Labs (synthetic heart valves and vascular grafts), Peptilogics (anti-infective for prosthetic joint infections), Phoenix Kinetics (synthetic meniscus replacement), Restor3d (3D-printed patient-specific implants), RevMedica (semi-reusable laparoscopic stapler), TYBR Health (post-operative recovery hydrogel), and Veradermics (non-hormonal hair regrowth therapeutic).
Team
- Nick Pachuda, D.P.M., Partner - Foot and ankle surgeon and former Global Head of External Innovation at Johnson & Johnson's orthopedic division; launched the Extremities Division at Arthrex (grew to $1B revenue); led teams behind exits totaling more than $22B including Small Bone Innovations, Scient'x, and Synthes; also serves as COO of portfolio company Peptilogics.
- Kevin Rocco, M.S., Partner - Founder and CEO of Biorez, a regenerative-medicine implant company acquired by CONMED in 2022 for up to $250M; holds B.S. and M.S. degrees in biomedical engineering from UConn and Yale; prior research at Yale in tissue engineering (17 publications) and engineering roles at Covidien (now Medtronic). Based in New Haven, CT.
- Matt Harbaugh, J.D./M.B.A., Partner - Co-founder of Mountain State Capital; formerly ran Innovation Works' $50M seed fund as Chief Investment Officer; CEO of Mobile Technologies, acquired by Facebook/Meta in 2013; has invested in or advised 100+ tech and life sciences startups. Based in Pittsburgh, PA.
The firm also maintains an exclusive strategic partnership with Precision Life Science Partners, a network of 70+ sub-sector experts from major multinational medtech and biopharma firms who support deal sourcing, diligence, and portfolio operations.
Decision Process
The firm is a small, three-partner shop (Pachuda, Rocco, Harbaugh), consistent with a partnership-style decision process rather than a solo GP or formal investment committee.
Founder Preferences
Based on the team's own operating and clinical backgrounds, Neovate appears to favor founders with strong clinical or technical credibility in life sciences - physician-founders, biomedical engineers, and operators who have previously built or scaled medtech companies.
Geographic Focus
The partners are distributed across Denver, CO, New Haven, CT, and Pittsburgh, PA, with no single disclosed headquarters. Portfolio activity is concentrated in the United States.